Ofran 8 mg/4 ml (IM/IV Injection)

4 ml ampoule: ৳ 32.00 (3 x 2: ৳ 192.00)

Medicine Details

Category Details
Generic Ondansetron
Company Square pharmaceuticals plc
Also available as
Ofran 8 mg tablet Ofran 4 mg oral solution

Indications

  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy
  • Prevention and treatment of post-operative nausea and vomiting
  • Prevention of radiotherapy-induced nausea and vomiting

Description

  • Oral soluble film
  • Orally dissolving film designed to be applied on top of the tongue
  • Dissolves within 20 seconds
  • Active ingredient: Ondansetron base
  • Empirical formula: C18H19N3O
  • Molecular weight: 293.3

Pharmacology

  • Selective blocking agent of the serotonin 5-HT3 receptor type
  • Exact mode of action not fully known
  • Blocks initiation of vomiting reflex
  • Antagonizes 5HT3 receptors in peripheral and central nervous system
  • Mechanism of action in post-operative nausea and vomiting not fully understood

Dosage

  • Various dosage forms and strengths for different patient populations
  • Dosage adjustments for patients with impaired renal or hepatic function
  • Specific dosing instructions for chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting

Administration

  • Step-by-step administration instructions for oral soluble film
  • No requirement for water for administration
  • Hand hygiene after administration

Interaction

  • Metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes
  • Potential for interaction with inducers or inhibitors of these enzymes

Contraindications

  • Hypersensitivity to the drug or any of its components
  • Concomitant use of apomorphine

Side Effects

  • Common adverse events: headache, constipation, diarrhea
  • Rare adverse events: rash, flushing, hiccups, liver enzyme abnormalities
  • Rare cases of anaphylaxis, bronchospasm, tachycardia, chest pain, hypokalemia, shortness of breath
  • No evidence of extrapyramidal reactions

Pregnancy & Lactation

  • No evidence of carcinogenic or mutagenic effects in animal studies
  • No evidence of impaired fertility or harm to fetus in animal studies
  • No adequate and well-controlled studies in pregnant women
  • Excreted in breast milk of rats, caution advised for nursing women

Precautions & Warnings

  • Hypersensitivity reactions reported in patients with hypersensitivity to other selective 5-HT3 receptor antagonists
  • Not a stimulant of gastric or intestinal peristalsis
  • Should not be used instead of nasogastric suction
  • May mask a progressive ileus and/or gastric distension

Use in Special Populations

  • Dosage adjustment for patients with impaired renal function
  • Dosage adjustment for patients with impaired hepatic function
  • Limited information available for pediatric patients 4 years of age or younger

Therapeutic Class

  • Anti-emetic drugs

Storage Conditions

  • Temperature not exceeding 30°C
  • Dry place
  • Protect from light and moisture

Related Brands